Knowledge Hub
Welcome to the PAN-Biotech Knowledge Hub, your central source for the latest company news, press releases, scientific publications, product innovations, awards, and biotechnology insights.
Here you will find updates on cell culture media, sera, serum-free media, buffers, water for injection (WFI), GMP manufacturing, and contract development and manufacturing (CDMO). The Newsroom also features articles on quality standards, regulatory developments, sustainability initiatives, research collaborations, and advancements in biotechnology and pharmaceutical manufacturing.
As a German manufacturer serving research institutions, biotechnology companies, and pharmaceutical organizations worldwide, PAN-Biotech shares expert knowledge, company developments, and industry achievements to support scientists, manufacturers, and partners across the life sciences sector.
Browse our latest publications to learn more about our technologies, products, services, industry recognition, and ongoing commitment to quality, innovation, and customer success.
Championing Quality and Speed from Research to Commercialization
CASE Studies
Proven with our customers
When the stakes were highest — an incumbent supplier exiting, a regulatory shutdown of a US site, a new private-label GMP line, a race against the clock — these companies turned to PAN-Biotech. Four partnerships, chosen examples from numerous similar cases, show the range across every grade, from RUO and for-further-manufacturing supply under PAN-Biotech to GMP production by PAN-Celltech in a dedicated EU Annex 1 facility.
Securing a product after a supplier discontinuation
When an incumbent supplier discontinued the product, an established owner faced an urgent gap — a new manufacturer was needed fast, with FDA product registration and full customisation. Under PAN Complete, one partner absorbed the whole transition end-to-end: registration, sourcing, production, QA/QC, labeling, storage and shipping. A supplier exit became a documented, secured supply.
A two-year OEM bridge after a regulatory shutdown
A regulatory shutdown took a global supplier's US manufacturing site offline. PAN-Biotech's owner committed at a trade-show booth, and in forty days — three audits, four jurisdictions, tech transfer, MBRs — went from a handshake to production-ready. Its people volunteered over the New Year to start on 2 January. Over two years PAN-Biotech delivered ~300,000 bottles across ~25 products, with no rejections recorded, until the customer's own site recovered.
A global manufacturer's private-label GMP line for Europe
A global, Japan-headquartered company set out to launch a private-label product line for European customers under GMP (EU Annex 1). PAN-Celltech built a tailored CMO/CDMO model — GMP process development for new and existing products, custom single-use packaging, full QC/QA, and GDP-ready handling — integrating into the partner's existing GMP environments. Now in ongoing supply.
50,000 litres of GMP supply in under five weeks
A vaccine manufacturer needed large-volume GMP supply on a timeline measured in weeks. PAN-Biotech quoted in three days, began production three weeks after the order, delivered the first shipment within two weeks, and completed ~50,000 litres in under five weeks — at GMP quality.
The common thread
Whether the need is RUO or for-further-manufacturing supply, an OEM bridge, or GMP production at speed, these partnerships share a spine: one stable, independent German manufacturer that spans the full grade range — RUO and FFM under PAN-Biotech, GMP by PAN-Celltech in a dedicated EU Annex 1 facility — and treats continuity, documentation and speed as the product. And for companies entering the European market, it is also a single qualified partner inside the EU for manufacturing, testing and logistics — our Gateway to Europe.
Technical paper · Water Solutions
WFI Beyond — Beyond Compendial
The water standard inside every GMP biologic, from monoclonal antibodies and mRNA to cell, gene and vaccine therapies.
1. Founded on water
In 1988, in the village of Aidenbach in Lower Bavaria, PAN-Biotech was founded for one simple reason: the water. The region sits on what the company’s founders considered some of the finest well water in Europe — and the conviction was not eccentric. A few kilometres away, the Cistercian monks of Kloster Aldersbach had been brewing beer on the very same groundwater since 1268 — a brewery documented from that year, and among the oldest in the world. And the parallel runs deeper than the water alone: brewing is itself a biological process — yeast cultured in water to harvest a product — the very principle on which modern cell culture, and the biologics industry PAN-Biotech serves, is built. Good water has been prized in this corner of Bavaria for the better part of a millennium.
For the thirty-eight years since, that water has been the quiet foundation of PAN-Biotech’s cell-culture media — the products that made the company’s name with biologics developers worldwide. Then PAN-Celltech was founded to carry that same foundation forward into GMP: to bring the group’s decades of water and bioprocess expertise to the demands of regulated, clinical-grade manufacturing.
2. The most underestimated raw material
In any biologics process, Water for Injection is everywhere and noticed nowhere. It is the base of almost every buffer and medium, and it is the vehicle for the final formulation that goes into the vial. No other single input touches so many stages of the process — or so many different kinds of processes.
That ubiquity is exactly why it is dangerous to underestimate. Because the water flows into nearly every step, its quality cascades into all of them: a deficiency in the water is not contained to one buffer, it is distributed across the entire process. The most ordinary-looking component is, at GMP scale, one of the hardest to guarantee consistently and to document — and the one whose quality is most quietly multiplied through everything it touches.
3. One water, every modality
What makes WFI unique among raw materials is that it is not specific to any one product. Antibodies, mRNA, cell and gene therapies, vaccines and recombinant proteins are built on profoundly different biology — but all of them rest on the same water. That is why a single, premium water standard can serve an entire pipeline, even as the molecules it supports could hardly be more different.
What changes from one modality to the next is not whether water quality matters, but which attribute matters most. The same WFI Beyond specification answers all of them; each application simply leans on a different part of it:
| Modality | What matters most in the water | Why |
|---|---|---|
| Monoclonal antibodies | Low trace metals; ultra-low endotoxin | Trace metal ions catalyse oxidation and drive aggregation, threatening stability; pyrogen control is essential in an injectable. |
| mRNA & LNP products | Nuclease-free (RNase) | Residual RNase degrades the mRNA payload — a direct hit to potency. For these products it is the single most important water attribute. |
| Cell & gene therapy | Ultra-low endotoxin; nuclease-free; sterility | Sensitive primary cells and nucleic-acid cargo, often patient-proximate, leave no margin for pyrogens or contamination. |
| Vaccines | Endotoxin control and sterility at scale | Pyrogen safety and batch-to-batch consistency must hold across large production volumes. |
| Recombinant proteins | Low endotoxin and organic carbon | Purity and pyrogen control protect the final product and keep the process clean. |
Read down the table and the conclusion is hard to miss: the case for a higher water standard does not weaken as you move beyond antibodies — it strengthens. For mRNA and cell and gene therapy in particular, the attributes that distinguish a premium WFI are not a refinement; they are central to whether the product works at all.
4. Beyond the monograph: what a premium water controls
“Water for Injection” is a pharmacopeial grade. To carry the name, water must meet a defined monograph — limits on conductivity, organic carbon, endotoxin and so on. That is a meaningful bar. But it is a floor, not a ceiling: it describes the minimum a water must clear to be called WFI, not the quality a particular batch delivers. Two waters can both be entirely legitimate WFI and still be worlds apart on the attributes that matter to an advanced biologic, because the monograph was written for injectable water in general — not for the specific vulnerabilities of these molecules. It helps to remember what the label actually is: “WFI” stands for Water for Injection, the pharmacopoeial grade of water permitted in injectable medicines — and the European standard for it dates back to the first European Pharmacopoeia, published in 1969, its limits framed in, and for, the medicine of that era.
That era was the age of small-molecule and classical injectable drugs; the biologics that dominate today’s pipelines did not yet exist. Recombinant proteins arrived only in the 1980s, therapeutic antibodies after them, and mRNA and cell and gene therapies within the last few years. The monograph is kept fully current — but its core purpose remains what it was: a safe baseline for injectable water in general, from the era of simpler molecules. It was never written around the vulnerabilities of a monoclonal antibody, an mRNA payload or a living cell. WFI Beyond starts from the other end: it is engineered for the medicine of today and tomorrow — built around exactly the attributes those modern modalities depend on.
Each of those vulnerabilities maps to a specific attribute of the water:
- Endotoxin. Pyrogenic and a direct patient-safety concern. The compendial limit (< 0.25 EU/mL) is a ceiling not to be exceeded — but the goal for a biologic is to sit as far below it as possible, not merely to clear it.
- Nucleases. Residual RNase and DNase degrade nucleic acids — a direct potency risk for mRNA and gene therapies, and a source of error in nucleic-acid analytical work.
- Trace / elemental impurities. Iron, copper and other ions catalyse oxidation and drive aggregation — a direct threat to protein stability and shelf life that conductivity alone does not capture.
- Conductivity / ionic purity. A compendial parameter in its own right; a low, stable conductivity reflects consistent ionic purity from batch to batch.
- Organic carbon (TOC). A general marker of purity: the lower the organic load, the fewer unknowns introduced into a sensitive process.
- Animal origin. A TSE/BSE and animal-component question runs through every regulatory filing. A clear animal-component-free position closes it before it is asked.
And the questions no longer end where the 1969 monograph does. A biologic reaching a patient today must account for impurity classes the monograph never named — and WFI Beyond addresses each of them in its documentation: elemental impurities to ICH Q3D (all 24 elements, by validated ICP-MS), residual solvents to ICH Q3C, a nitrosamine risk assessment to current EMA guidance — the class that forced global drug recalls from 2018 onward — and TSE/BSE, from exclusively non-animal materials outside the scope of EMA/410/01. That is the impurity dossier a modern filing actually has to clear, prepared in advance.
5. The WFI Beyond standard
WFI Beyond is built to go beyond the monograph on exactly the attributes that matter — across every modality. “Beyond compendial” is not a slogan; it is a measured fact, certified lot by lot on the Certificate of Analysis.
| Attribute | WFI Beyond | Why it matters |
|---|---|---|
| Endotoxin | < 0.005 EU/mL — more than 50× below the 0.25 EU/mL compendial limit | Minimises pyrogenic risk far beyond the monograph floor |
| Total organic carbon 1 | < 0.05 mg/L — more than 10× below the 0.5 mg/L limit | Exceptional organic purity; fewer unknowns in a sensitive process |
| Conductivity 1 | < 0.2 µS/cm (20 °C) — more than 5× below the 1.1 µS/cm limit | Exceptional ionic purity, well beyond the compendial WFI standard |
| Appearance | Clear and colourless liquid | Confirms a clear, colourless water as required for injectable-grade use |
| Nuclease activity | RNase & DNase not detected (fluorometric) | Protects nucleic acids — critical for mRNA and gene therapies |
| Elemental impurities | All 24 elemental impurities, by ICP-MS, to ICH Q3D — with the measured values on every CoA | A finished-drug standard applied to water; hands you the data for your own ICH Q3D assessment |
| Nitrosamines | Nitrosamine risk assessed to current EMA guidance | Addresses the impurity class behind global drug recalls from 2018 onward |
| Sterility | Sterile — 0.1 µm filtered; single-use, gamma-irradiated to SAL 10⁻⁶ | Ready to use; removes a contamination entry point at your end |
| Animal origin | Animal-component-free; TSE/BSE statement | Closes a regulatory and safety question across the chain |
| Regulatory support | Filed FDA Type IV DMF (MF044505) | Reference it directly in your submission; our data backs your filing |
1 Conductivity and total organic carbon are measured continuously, online in the storage loop ahead of filtration and filling.
Made and assured under GMP. WFI Beyond is manufactured by PAN-Celltech under EU GMP Annex 1 within an ISO 9001 quality system. Aseptic filling is validated by routine media fills performed twice a year, in line with Annex 1. And it is backed by an ICH-format stability study supporting a two-year shelf life — tracked on sterility and endotoxin, at +15 to +25 °C. For a raw material that feeds an entire process, a proven shelf life and a validated aseptic process are not details; they are part of the assurance the product carries, from delivery through use.
Sterile by design. The bulk is sterile-filtered through a 0.1 µm filter — a full grade tighter than the 0.2 µm sterilising filter most processes rely on, and into the range that also retains mycoplasma-sized organisms — and filled aseptically in Grade A. Every product-contact component is sterile and single-use; the single-use containers are supplied pre-sterilised (e.g. gamma-irradiated, to a validated dose under ISO 11137, reaching a Sterility Assurance Level of 10⁻⁶) as a prerequisite for filling, with in-process controls and environmental and operator monitoring throughout. The whole is run to the frameworks a modern filing expects: EU GMP Annex 1, ICH Q7, 21 CFR Part 211 and ISO 13408, with every batch traceable from source water to release.
6. From source to single-use bag
A premium source is the beginning of the story, not the end of it. WFI quality is ultimately made by purification and control, not by the well alone — and then proven by testing and documentation. Every lot is tested against the specification and supplied with a Certificate of Analysis; nitrosamines and TSE/BSE are addressed by assessment. Under GMP, that documentation is not paperwork around the product — it is part of the product.
The regulatory keystone. Of everything in that package, the Drug Master File does the most work. WFI Beyond is now backed by a Drug Master File filed with the US FDA (MF044505); the group also holds a filed DPBS DMF (MF044371). A DMF on file lets you reference our confidential manufacturing and quality data directly in your own regulatory submission — through a simple letter of authorisation — so the authority can rely on it in full without your team ever obtaining, holding or recreating it, and without proprietary detail being exposed in either direction. It removes one of the heaviest items a lean QA function would otherwise build from scratch, and it measurably de-risks and shortens your filing. For an input as fundamental as water, a DMF is the difference between buying from a supplier and building on a regulatory partner.
Single-use where it touches the product. WFI Beyond is made and filled on a single-use, gamma-irradiated product-contact path. Every product-contact part is single-use and replaced for each batch; the only re-used item is a single small component dedicated exclusively to WFI Beyond water production and steam-sterilised (autoclaved) after every use — so there is no shared, multi-product equipment and no cleaning-residue or batch-to-batch carry-over on the product-contact path. It is supplied in single-use, gamma-irradiated packaging; the container-closure system is qualified for both bottles and bags, and the film screened for extractables — DEHP and other phthalates, Bisphenol A, dioxin and melamine were not identified.
It scales seamlessly with your programme — from 500 mL and 1000 mL bottles to single-use, gamma-irradiated bags from 1 to 1000 litres (1, 5, 10, 20, 50, 200, 500 and 1000 L) — so the same qualified water follows you from development to production, and across every modality in your pipeline, without re-qualifying the supply at every step.
7. Conclusion
Water is the input every biologics process takes for granted and the one whose quality reaches furthest. “Meets WFI” tells you a water cleared the floor; it does not tell you whether it was made for your molecule. WFI Beyond is nuclease-free, animal-component-free, low in organic carbon and elemental impurities, sterile and single-use, with endotoxin roughly fifty times below the compendial limit and organic carbon more than ten times below it — all certified on a Certificate of Analysis and backed by a filed FDA Drug Master File.
Because it is the one standard shared by antibodies, mRNA, cell and gene therapies and vaccines alike, WFI Beyond can sit beneath an entire pipeline — a single qualified water you grow with, whatever you are making. It comes, fittingly, from a group founded on water in 1988 and built to bring it to GMP. For a modern biologic, that foundation is not a nice story — it is the difference between water that complies and water that protects.
See the WFI Beyond product page Request the specification, CoA or DMF letter of authorization
Frequently asked questions
What does “beyond compendial” mean for Water for Injection?
It means the water is controlled to exceed the Ph. Eur./USP Water-for-Injection monograph rather than merely meet it. WFI Beyond sits more than 50× below the endotoxin limit, more than 10× below the organic-carbon limit and more than 5× below the conductivity limit, adds nuclease testing and a nitrosamine risk assessment the monograph does not require, and reports all 24 ICH Q3D elemental impurities on every Certificate of Analysis.
Why isn’t “meets WFI” enough for a modern biologic?
The European WFI monograph dates back to the first European Pharmacopoeia of 1969 — and although it has been kept fully current ever since, its core purpose remains to define a safe baseline for injectable water in general, not the specific vulnerabilities of a modern biologic. “Meets WFI” tells you a water cleared that floor; it does not tell you whether it was controlled for the vulnerabilities of your molecule — metal-catalysed aggregation, nuclease degradation, pyrogen safety at ultra-low levels.
Is WFI Beyond backed by a Drug Master File?
Yes — a filed FDA Type IV Drug Master File, MF044505. You can reference our confidential manufacturing and quality data in your own submission through a simple letter of authorization, so the authority can rely on it in full without your team obtaining, holding or recreating it.
Is WFI Beyond nuclease-free?
Yes — RNase and DNase are not detected by fluorometric testing, protecting mRNA and nucleic-acid payloads. Nitrosamines are addressed separately, by a risk assessment to current EMA guidance rather than a blanket “free” claim.
What is different about WFI Beyond’s elemental testing?
ICH Q3D is a finished-drug standard; the WFI monograph does not call for it. WFI Beyond applies it to water anyway — all 24 elemental impurities, measured by validated ICP-MS, with the actual values on every Certificate of Analysis rather than a pass/fail. It is a level of elemental characterisation so far beyond convention that our accredited laboratory had not been asked to run it on Water for Injection before.
How is sterility assured?
The bulk is sterile-filtered through a 0.1 µm filter — tighter than the usual 0.2 µm and into the range that retains mycoplasma-sized organisms — and filled aseptically in Grade A. Every product-contact component is sterile and single-use; the containers are supplied pre-sterilised (e.g. gamma-irradiated to a validated dose under ISO 11137, SAL 10⁻⁶) as a prerequisite for filling.
Related: WFI Beyond (product) · WFI Quality Water · Sterile Water for Cell Culture · Water Solutions